Sickle cell disease, pathophysiology and clinical complications

van Beers, E.J.

Citation for published version (APA):
CONTENTS

Part I: General overview and clinical complications

1 Pathophysiology and treatment of sickle cell disease...........................................7

2 Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial.................................................................21

3 Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice.............................................................37

4 Normal sublingual microcirculation during painful crisis in sickle cell disease.................................................................................................49

Part II: Pathophysiology

5 Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease..........................................................63

6 Sickle cell patients are characterized by a reduced glycocalyx volume..................................................................................................................77
Part III: Pulmonary hypertension

7 Large and medium-sized pulmonary artery obstruction does not play a role of primary importance in the etiology of sickle cell disease-associated pulmonary hypertension. ..................................................91

8 No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension. ..................................105

9 Association of asymmetric dimethylarginine with sickle cell disease related pulmonary hypertension. ...............................117

10 Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension. ..........................................................129

11 Decreased exercise tolerance and pulmonary hypertension in patients with sickle cell disease. .................................................................149

12 Summary, ......................................................................................................................165

13 Dankwoord, ..................................................................................................................177

14 Curriculum Vitae, ........................................................................................................185